Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

The Impact of Gender on Tumour Stage in In-House Complications and Choice of Urinary Diversion: Results of the Austrian Cystectomy Registry.

Gschliesser T, Eredics K, Berger I, Szelinger M, Klingler HC, Colombo T, Ponholzer A, Plas E, Grubmüller K, Dunzinger M, Jeschke K, Würnschimmel E, Krause FS, Shariat S, Leeb K, Pelzer A, Riedl C, Rauchenwald M, Hübner W, Brössner C, Madersbacher S; Cystectomy Registry of the Austrian Society of Urology.

Urol Int. 2017;99(4):429-435. doi: 10.1159/000477672. Epub 2017 Jun 23.

PMID:
28641294
2.

Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy.

Bertz S, Wach S, Taubert H, Merten R, Krause FS, Schick S, Ott OJ, Weigert E, Dworak O, Rödel C, Fietkau R, Wullich B, Keck B, Hartmann A.

Virchows Arch. 2016 Sep;469(3):339-44. doi: 10.1007/s00428-016-1986-x. Epub 2016 Jul 8.

PMID:
27392930
3.

How Octogenarians with Bladder Cancer Are Treated in a Maximum-Care Hospital: The Real-Life Experience.

Sikic D, Wach S, Taubert H, Richterstetter M, Kunath F, Lieb V, Krause FS, Merten R, Ott O, Fietkau R, Wullich B, Keck B.

Urol Int. 2017;98(3):262-267. doi: 10.1159/000447361. Epub 2016 Jul 5.

PMID:
27376673
4.

Efficacy Management of Urolithiasis: Flexible Ureteroscopy versus Extracorporeal Shockwave Lithotripsy.

Tauber V, Wohlmuth M, Hochmuth A, Schimetta W, Krause FS.

Urol Int. 2015;95(3):324-8. doi: 10.1159/000439356. Epub 2015 Sep 23. Erratum in: Urol Int. 2015;95(4):477. Schimetta, Wofgang [Corrected to Schimetta, Wolfgang].

PMID:
26393912
5.

Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients.

Keck B, Wach S, Taubert H, Zeiler S, Ott OJ, Kunath F, Hartmann A, Bertz S, Weiss C, Hönscheid P, Schellenburg S, Rödel C, Baretton GB, Sauer R, Fietkau R, Wullich B, Krause FS, Datta K, Muders MH.

Int J Cancer. 2015 Jan 15;136(2):443-51. doi: 10.1002/ijc.28987. Epub 2014 Jun 12.

6.

Metabolic engineering of Corynebacterium glutamicum for 2-ketoisocaproate production.

Bückle-Vallant V, Krause FS, Messerschmidt S, Eikmanns BJ.

Appl Microbiol Biotechnol. 2014 Jan;98(1):297-311. doi: 10.1007/s00253-013-5310-2. Epub 2013 Oct 30.

PMID:
24169948
7.

Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy.

Keck B, Ott OJ, Häberle L, Kunath F, Weiss C, Rödel C, Sauer R, Fietkau R, Wullich B, Krause FS.

World J Urol. 2013 Oct;31(5):1023-8. doi: 10.1007/s00345-012-0971-5. Epub 2012 Oct 23.

PMID:
23090757
8.

Magnetic resonance image-guided biopsies with a high detection rate of prostate cancer.

Engehausen DG, Engelhard K, Schwab SA, Uder M, Wach S, Wullich B, Krause FS.

ScientificWorldJournal. 2012;2012:975971. doi: 10.1100/2012/975971. Epub 2012 Mar 12.

9.

Assessment and characterisation of common renal masses with CT and MRI.

Pallwein-Prettner L, Flöry D, Rotter CR, Pogner K, Syré G, Fellner C, Frauscher F, Aigner F, Krause FS, Fellner F.

Insights Imaging. 2011 Oct;2(5):543-556. Epub 2011 Jul 17.

10.

The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer.

Richterstetter M, Wullich B, Amann K, Haeberle L, Engehausen DG, Goebell PJ, Krause FS.

BJU Int. 2012 Jul;110(2 Pt 2):E76-9. doi: 10.1111/j.1464-410X.2011.10904.x. Epub 2012 Feb 7.

11.

15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment.

Krause FS, Walter B, Ott OJ, Häberle L, Weiss C, Rödel C, Wullich B, Sauer R.

Anticancer Res. 2011 Mar;31(3):985-90.

PMID:
21498726
12.

Metabolic engineering of Corynebacterium glutamicum for 2-ketoisovalerate production.

Krause FS, Blombach B, Eikmanns BJ.

Appl Environ Microbiol. 2010 Dec;76(24):8053-61. doi: 10.1128/AEM.01710-10. Epub 2010 Oct 8.

13.

Diagnostic challenge of atypical colorectal metastasis to the renal pelvis.

Keck B, Rau T, Krause FS, Walter B, Goebell PJ, Hartmann A, Wullich B.

Int J Colorectal Dis. 2011 Apr;26(4):523-4. doi: 10.1007/s00384-010-0987-5. Epub 2010 Jun 17. No abstract available. Erratum in: Int J Colorectal Dis. 2010 Nov;25(11):1387. Bastian, Keck [corrected to Keck, Bastian]; Tilman, Rau T [corrected to Rau, Tilman]; Frens, Krause S [corrected to Krause, Frens Steffen]; Bernhardt, Walter [corrected to Walter, Bernhard]; Peter, Goebell J [corrected to Goebell, Peter J]; Arndt, Hartmann.

PMID:
20556400
14.

Increased glucose utilization in Corynebacterium glutamicum by use of maltose, and its application for the improvement of L-valine productivity.

Krause FS, Henrich A, Blombach B, Krämer R, Eikmanns BJ, Seibold GM.

Appl Environ Microbiol. 2010 Jan;76(1):370-4. doi: 10.1128/AEM.01553-09. Epub 2009 Oct 30.

15.

[Value of radical oncological surgery in bilateral synchronous renal cell cancer and coincidental simultaneous prostate cancer].

Rud O, Krause FS, Engehausen DG, May M, Gilfrich C.

Aktuelle Urol. 2009 Sep;40(5):300-2. doi: 10.1055/s-0029-1224518. Epub 2009 Jul 14. German.

PMID:
19603378
16.

Serotonin used as prognostic marker of urological tumors.

Jungwirth N, Haeberle L, Schrott KM, Wullich B, Krause FS.

World J Urol. 2008 Oct;26(5):499-504. doi: 10.1007/s00345-008-0285-9. Epub 2008 Jun 26.

PMID:
18581119
17.

Solitary metastasis of a Merkel cell tumor to the urinary bladder.

Strasser H, Amann K, Schrott KM, Krause FS.

Anticancer Res. 2008 Mar-Apr;28(2B):1361-4.

18.

Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.

Weiss C, Wittlinger M, Engehausen DG, Krause FS, Ott OJ, Dunst J, Sauer R, Rödel C.

Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1502-6. Epub 2007 Nov 1.

PMID:
17935905
19.

Polymorphisms of human estrogen receptor (ER) gene alpha and beta in prostate cancer PC-EW and PC-OR cell lines.

Bergner CC, Krause FS, Zugor V, Rith T, Schrott KM, Endele S, Engehausen DG.

Anticancer Res. 2007 Jul-Aug;27(4A):2071-4.

20.

Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer.

Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R, Rödel C.

Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1072-80. Epub 2007 Apr 30.

PMID:
17467193
21.

MRI spectroscopy in screening of prostate cancer.

Goeb K, Engehausen DG, Krause FS, Hollenbach HP, Niedobitek G, Buettner M, Frangou P, Engelhard K.

Anticancer Res. 2007 Jan-Feb;27(1B):687-93.

22.

[B-cell lymphoma of the testes].

Zugor V, Frank M, Krause FS, Schott GE, Aigner T, Engehausen DG.

Urologe A. 2006 Oct;45(10):1308-11. German.

PMID:
16788784
23.

Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?

Weiss C, Wolze C, Engehausen DG, Ott OJ, Krause FS, Schrott KM, Dunst J, Sauer R, Rödel C.

J Clin Oncol. 2006 May 20;24(15):2318-24.

PMID:
16710030
24.

Clinical decisions for treatment of different staged bladder cancer based on multitarget fluorescence in situ hybridization assays?

Krause FS, Rauch A, Schrott KM, Engehausen DG.

World J Urol. 2006 Sep;24(4):418-22. Epub 2006 May 11.

PMID:
16688457
25.

Heterogeneity in prostate cancer: prostate specific antigen (PSA) and DNA cytophotometry.

Krause FS, Feil G, Bichler KH, Schrott KM, Akcetin ZY, Engehausen DG.

Anticancer Res. 2005 May-Jun;25(3A):1783-5.

26.

Does the distance to normal renal parenchyma (DTNRP) in nephron-sparing surgery for renal cell carcinoma have an effect on survival?

Akçetin Z, Zugor V, Elsässer D, Krause FS, Lausen B, Schrott KM, Engehausen DG.

Anticancer Res. 2005 May-Jun;25(3A):1629-32.

27.

Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer.

Akçetin Z, Todorov J, Tüzel E, Engehausen DG, Krause FS, Sauer R, Schrott KM, Rödel C.

Anticancer Res. 2005 May-Jun;25(3A):1623-8.

28.

Polymorphisms of human androgen receptor (hAR) gene in prostate cancer cell lines PC-EW and PC-OR.

Engehausen DG, Krause FS, Fleischmann J, Akcetin Z, Schrott KM, Endele S.

Anticancer Res. 2005 May-Jun;25(3A):1611-4.

29.

Ki67, p53, nm23, and DNA cytometry in bladder cancer: potential markers for detection of recurrence?

Feil G, Krause FS, Zumbraegel A, Wechsel HW, Bichler KH.

Adv Exp Med Biol. 2003;539(Pt A):99-109. No abstract available.

PMID:
15088899
30.

Detection of HER-2/neu CEP 17 mutations at invasive bladder cancer.

Feil G, Krause FS, Zumbraegel A, Bichler KH.

Adv Exp Med Biol. 2003;539(Pt A):87-97. No abstract available.

PMID:
15088898
31.

The photodynamic diagnosis (PDD) for early detection of carcinoma and dysplasia of the bladder.

Zumbraegel A, Bichler KH, Krause FS, Feil G, Nelde HJ.

Adv Exp Med Biol. 2003;539(Pt A):61-6. No abstract available.

PMID:
15088896
32.

Clinical aspects for the use of DNA image cytometry in detection of bladder cancer: a valuable tool?

Krause FS, Feil G, Bichler KH, Schrott KM, Akcetin ZY.

DNA Cell Biol. 2003 Nov;22(11):721-5.

PMID:
14659044
33.

Immunohistochemical examinations (Ki67, p53, nm23) and DNA cytophotometry in bladder cancer.

Krause FS, Feil G, Bichler KH.

Anticancer Res. 2000 Nov-Dec;20(6D):5023-8.

PMID:
11326661
34.

Molecular genetic methods in the diagnosis of invasive bladder cancer.

Krause FS, Feil G, Zumbrägel A, Bichler KH.

Anticancer Res. 2000 Nov-Dec;20(6D):5015-21.

PMID:
11326660
35.

[Bilateral renal oncocytoma].

Moisin L, Krause FS.

Rontgenpraxis. 1998 Mar;51(1-2):43-5. German. No abstract available.

PMID:
9594638

Supplemental Content

Loading ...
Support Center